Pyrazinamide (English Wikipedia)

Donald PR, van Helden PD (2011). Antituberculosis Chemotherapy. Karger Medical and Scientific Publishers. p. 8. ISBN 978-3-8055-9628-2. Archived from the original on 10 September 2017.

doi.org (Global: 2^nd place; English: 2^nd place)

Hannan MM, Desmond EP, Morlock GP, Mzurek GH, Crawford JT (2001). "Pyrazinamide-Monoresistant Mycobacterium tuberculosis in the United States". Journal of Clinical Microbiology. 39 (2): 647–650. doi:10.1128/JCM.39.2.647-650.2001. PMC 87792. PMID 11158123.
Hong Kong Chest Service/British Medical Research Council (January 1981). "Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis". Lancet. 1 (8213): 171–174. doi:10.1016/S0140-6736(81)90057-X. PMID 6109855.
Third East African/British Medical Research Council Study (June 1980). "Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study". Tubercle. 61 (2): 59–69. doi:10.1016/0041-3879(80)90012-4. PMID 6159711.
Spaia S, Magoula I, Tsapas G, Vayonas G (2000). "Effect of pyrazinamide and probenecid on peritoneal urate transport kinetics during continuous ambulatory peritoneal dialysis". Peritoneal Dialysis International. 20 (1): 47–52. doi:10.1177/089686080002000109. PMID 10716583. S2CID 19352495.
Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. (January 2004). "Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion". Journal of the American Society of Nephrology. 15 (1): 164–173. doi:10.1097/01.ASN.0000105320.04395.D0. PMID 14694169.
"Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis". Tubercle. 64 (3): 153–166. September 1983. doi:10.1016/0041-3879(83)90011-9. PMID 6356538.
British Thoracic Society (October 1984). "A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society". British Journal of Diseases of the Chest. 78 (4): 330–336. doi:10.1016/0007-0971(84)90165-7. PMID 6386028.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (June 2003). "Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis". American Journal of Respiratory and Critical Care Medicine. 167 (11): 1472–1477. doi:10.1164/rccm.200206-626OC. PMID 12569078.
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. (February 2003). "American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis". American Journal of Respiratory and Critical Care Medicine. 167 (4): 603–662. doi:10.1164/rccm.167.4.603. PMID 12588714.
Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, et al. (28 July 2015). "A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis". PLOS ONE. 10 (7) e0133869. Bibcode:2015PLoSO..1033869W. doi:10.1371/journal.pone.0133869. PMC 4517823. PMID 26218737.
Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR (September 2000). "Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis". Nature Medicine. 6 (9): 1043–1047. doi:10.1038/79558. PMID 10973326. S2CID 7409751.
Boshoff HI, Mizrahi V, Barry CE (April 2002). "Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I". Journal of Bacteriology. 184 (8): 2167–2172. doi:10.1128/JB.184.8.2167-2172.2002. PMC 134955. PMID 11914348.
Zhang Y, Shi W, Zhang W, Mitchison D (2014). "Mechanisms of Pyrazinamide Action and Resistance". Microbiology Spectrum. 2 (4) 2.4.03. doi:10.1128/microbiolspec.mgm2-0023-2013. PMC 4268777. PMID 25530919.
Peterson ND, Rosen BC, Dillon NA, Baughn AD (December 2015). "Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 59 (12): 7320–7326. doi:10.1128/aac.00967-15. PMC 4649215. PMID 26369957.
Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, et al. (September 2011). "Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis". Science. 333 (6049): 1630–1632. Bibcode:2011Sci...333.1630S. doi:10.1126/science.1208813. PMC 3502614. PMID 21835980.
Dillon NA, Peterson ND, Feaga HA, Keiler KC, Baughn AD (July 2017). "Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA". Scientific Reports. 7 (1) 6135. Bibcode:2017NatSR...7.6135D. doi:10.1038/s41598-017-06415-5. PMC 5522395. PMID 28733601.
Gopal P, Sarathy JP, Yee M, Ragunathan P, Shin J, Bhushan S, et al. (April 2020). "Pyrazinamide triggers degradation of its target aspartate decarboxylase". Nature Communications. 11 (1): 1661. Bibcode:2020NatCo..11.1661G. doi:10.1038/s41467-020-15516-1. PMC 7125159. PMID 32245967.
Scorpio A, Zhang Y (June 1996). "Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus". Nature Medicine. 2 (6): 662–667. doi:10.1038/nm0696-662. PMID 8640557. S2CID 8579133.
Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F (January 2010). "Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide". Journal of Clinical Microbiology. 48 (1): 300–301. doi:10.1128/JCM.01775-09. PMC 2812260. PMID 19923479.
Piersimoni C, Mustazzolu A, Iacobino A, Giannoni F, Santoro G, Gherardi G, et al. (December 2016). "Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system". The International Journal of Tuberculosis and Lung Disease. 20 (12): 1677–1680. doi:10.5588/ijtld.16.0360. PMID 27931346.
Juréen P, Werngren J, Toro JC, Hoffner S (May 2008). "Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 52 (5): 1852–1854. doi:10.1128/AAC.00110-08. PMC 2346646. PMID 18316515.
Speirs RJ, Welch JT, Cynamon MH (June 1995). "Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide". Antimicrobial Agents and Chemotherapy. 39 (6): 1269–1271. doi:10.1128/aac.39.6.1269. PMC 162725. PMID 7574514.
Klemens SP, Sharpe CA, Cynamon MH (January 1996). "Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility". Antimicrobial Agents and Chemotherapy. 40 (1): 14–16. doi:10.1128/AAC.40.1.14. PMC 163048. PMID 8787871.
Sheen P, Requena D, Gushiken E, Gilman RH, Antiparra R, Lucero B, et al. (October 2017). "A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance". BMC Genomics. 18 (1) 769. doi:10.1186/s12864-017-4146-z. PMC 5637355. PMID 29020922.

drugs.com (Global: 529^th place; English: 550^th place)

"Pyrazinamide". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.

hdl.handle.net (Global: 66^th place; English: 34^th place)

Stuart MC, Kouimtzi M, Hill SR, eds. (2009). WHO Model Formulary. World Health Organization. pp. 136, 140, 594, 608. hdl:10665/44053. ISBN 978-92-4-154765-9.
Organization WH (2019). World Health Organization model list of essential medicines: 21st list. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

ingenta.com (Global: low place; English: low place)

openurl.ingenta.com

Zhang Y, Mitchison D (January 2003). "The curious characteristics of pyrazinamide: a review". The International Journal of Tuberculosis and Lung Disease. 7 (1): 6–21. PMID 12701830.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Hannan MM, Desmond EP, Morlock GP, Mzurek GH, Crawford JT (2001). "Pyrazinamide-Monoresistant Mycobacterium tuberculosis in the United States". Journal of Clinical Microbiology. 39 (2): 647–650. doi:10.1128/JCM.39.2.647-650.2001. PMC 87792. PMID 11158123.
Hong Kong Chest Service/British Medical Research Council (January 1981). "Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis". Lancet. 1 (8213): 171–174. doi:10.1016/S0140-6736(81)90057-X. PMID 6109855.
Third East African/British Medical Research Council Study (June 1980). "Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study". Tubercle. 61 (2): 59–69. doi:10.1016/0041-3879(80)90012-4. PMID 6159711.
Spaia S, Magoula I, Tsapas G, Vayonas G (2000). "Effect of pyrazinamide and probenecid on peritoneal urate transport kinetics during continuous ambulatory peritoneal dialysis". Peritoneal Dialysis International. 20 (1): 47–52. doi:10.1177/089686080002000109. PMID 10716583. S2CID 19352495.
Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. (January 2004). "Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion". Journal of the American Society of Nephrology. 15 (1): 164–173. doi:10.1097/01.ASN.0000105320.04395.D0. PMID 14694169.
"Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis". Tubercle. 64 (3): 153–166. September 1983. doi:10.1016/0041-3879(83)90011-9. PMID 6356538.
British Thoracic Society (October 1984). "A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society". British Journal of Diseases of the Chest. 78 (4): 330–336. doi:10.1016/0007-0971(84)90165-7. PMID 6386028.
American Thoracic Society, CDC, Infectious Diseases Society of America (June 2003). "Treatment of tuberculosis". MMWR. Recommendations and Reports. 52 (RR–11): 1–77. PMID 12836625.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (June 2003). "Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis". American Journal of Respiratory and Critical Care Medicine. 167 (11): 1472–1477. doi:10.1164/rccm.200206-626OC. PMID 12569078.
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. (February 2003). "American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis". American Journal of Respiratory and Critical Care Medicine. 167 (4): 603–662. doi:10.1164/rccm.167.4.603. PMID 12588714.
Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, et al. (28 July 2015). "A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis". PLOS ONE. 10 (7) e0133869. Bibcode:2015PLoSO..1033869W. doi:10.1371/journal.pone.0133869. PMC 4517823. PMID 26218737.
Zhang Y, Mitchison D (January 2003). "The curious characteristics of pyrazinamide: a review". The International Journal of Tuberculosis and Lung Disease. 7 (1): 6–21. PMID 12701830.
Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR (September 2000). "Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis". Nature Medicine. 6 (9): 1043–1047. doi:10.1038/79558. PMID 10973326. S2CID 7409751.
Boshoff HI, Mizrahi V, Barry CE (April 2002). "Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I". Journal of Bacteriology. 184 (8): 2167–2172. doi:10.1128/JB.184.8.2167-2172.2002. PMC 134955. PMID 11914348.
Zhang Y, Shi W, Zhang W, Mitchison D (2014). "Mechanisms of Pyrazinamide Action and Resistance". Microbiology Spectrum. 2 (4) 2.4.03. doi:10.1128/microbiolspec.mgm2-0023-2013. PMC 4268777. PMID 25530919.
Peterson ND, Rosen BC, Dillon NA, Baughn AD (December 2015). "Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 59 (12): 7320–7326. doi:10.1128/aac.00967-15. PMC 4649215. PMID 26369957.
Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, et al. (September 2011). "Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis". Science. 333 (6049): 1630–1632. Bibcode:2011Sci...333.1630S. doi:10.1126/science.1208813. PMC 3502614. PMID 21835980.
Dillon NA, Peterson ND, Feaga HA, Keiler KC, Baughn AD (July 2017). "Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA". Scientific Reports. 7 (1) 6135. Bibcode:2017NatSR...7.6135D. doi:10.1038/s41598-017-06415-5. PMC 5522395. PMID 28733601.
Gopal P, Sarathy JP, Yee M, Ragunathan P, Shin J, Bhushan S, et al. (April 2020). "Pyrazinamide triggers degradation of its target aspartate decarboxylase". Nature Communications. 11 (1): 1661. Bibcode:2020NatCo..11.1661G. doi:10.1038/s41467-020-15516-1. PMC 7125159. PMID 32245967.
Scorpio A, Zhang Y (June 1996). "Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus". Nature Medicine. 2 (6): 662–667. doi:10.1038/nm0696-662. PMID 8640557. S2CID 8579133.
Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F (January 2010). "Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide". Journal of Clinical Microbiology. 48 (1): 300–301. doi:10.1128/JCM.01775-09. PMC 2812260. PMID 19923479.
Piersimoni C, Mustazzolu A, Iacobino A, Giannoni F, Santoro G, Gherardi G, et al. (December 2016). "Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system". The International Journal of Tuberculosis and Lung Disease. 20 (12): 1677–1680. doi:10.5588/ijtld.16.0360. PMID 27931346.
Juréen P, Werngren J, Toro JC, Hoffner S (May 2008). "Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 52 (5): 1852–1854. doi:10.1128/AAC.00110-08. PMC 2346646. PMID 18316515.
Speirs RJ, Welch JT, Cynamon MH (June 1995). "Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide". Antimicrobial Agents and Chemotherapy. 39 (6): 1269–1271. doi:10.1128/aac.39.6.1269. PMC 162725. PMID 7574514.
Klemens SP, Sharpe CA, Cynamon MH (January 1996). "Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility". Antimicrobial Agents and Chemotherapy. 40 (1): 14–16. doi:10.1128/AAC.40.1.14. PMC 163048. PMID 8787871.
Sheen P, Requena D, Gushiken E, Gilman RH, Antiparra R, Lucero B, et al. (October 2017). "A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance". BMC Genomics. 18 (1) 769. doi:10.1186/s12864-017-4146-z. PMC 5637355. PMID 29020922.
Zhang Y, Mitchison D (January 2003). "The curious characteristics of pyrazinamide: a review". The International Journal of Tuberculosis and Lung Disease. 7 (1): 6–21. PMID 12701830.

ncbi.nlm.nih.gov

Hannan MM, Desmond EP, Morlock GP, Mzurek GH, Crawford JT (2001). "Pyrazinamide-Monoresistant Mycobacterium tuberculosis in the United States". Journal of Clinical Microbiology. 39 (2): 647–650. doi:10.1128/JCM.39.2.647-650.2001. PMC 87792. PMID 11158123.
Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, et al. (28 July 2015). "A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis". PLOS ONE. 10 (7) e0133869. Bibcode:2015PLoSO..1033869W. doi:10.1371/journal.pone.0133869. PMC 4517823. PMID 26218737.
Boshoff HI, Mizrahi V, Barry CE (April 2002). "Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I". Journal of Bacteriology. 184 (8): 2167–2172. doi:10.1128/JB.184.8.2167-2172.2002. PMC 134955. PMID 11914348.
Zhang Y, Shi W, Zhang W, Mitchison D (2014). "Mechanisms of Pyrazinamide Action and Resistance". Microbiology Spectrum. 2 (4) 2.4.03. doi:10.1128/microbiolspec.mgm2-0023-2013. PMC 4268777. PMID 25530919.
Peterson ND, Rosen BC, Dillon NA, Baughn AD (December 2015). "Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 59 (12): 7320–7326. doi:10.1128/aac.00967-15. PMC 4649215. PMID 26369957.
Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, et al. (September 2011). "Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis". Science. 333 (6049): 1630–1632. Bibcode:2011Sci...333.1630S. doi:10.1126/science.1208813. PMC 3502614. PMID 21835980.
Dillon NA, Peterson ND, Feaga HA, Keiler KC, Baughn AD (July 2017). "Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA". Scientific Reports. 7 (1) 6135. Bibcode:2017NatSR...7.6135D. doi:10.1038/s41598-017-06415-5. PMC 5522395. PMID 28733601.
Gopal P, Sarathy JP, Yee M, Ragunathan P, Shin J, Bhushan S, et al. (April 2020). "Pyrazinamide triggers degradation of its target aspartate decarboxylase". Nature Communications. 11 (1): 1661. Bibcode:2020NatCo..11.1661G. doi:10.1038/s41467-020-15516-1. PMC 7125159. PMID 32245967.
Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F (January 2010). "Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide". Journal of Clinical Microbiology. 48 (1): 300–301. doi:10.1128/JCM.01775-09. PMC 2812260. PMID 19923479.
Juréen P, Werngren J, Toro JC, Hoffner S (May 2008). "Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis". Antimicrobial Agents and Chemotherapy. 52 (5): 1852–1854. doi:10.1128/AAC.00110-08. PMC 2346646. PMID 18316515.
Speirs RJ, Welch JT, Cynamon MH (June 1995). "Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide". Antimicrobial Agents and Chemotherapy. 39 (6): 1269–1271. doi:10.1128/aac.39.6.1269. PMC 162725. PMID 7574514.
Klemens SP, Sharpe CA, Cynamon MH (January 1996). "Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility". Antimicrobial Agents and Chemotherapy. 40 (1): 14–16. doi:10.1128/AAC.40.1.14. PMC 163048. PMID 8787871.
Sheen P, Requena D, Gushiken E, Gilman RH, Antiparra R, Lucero B, et al. (October 2017). "A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance". BMC Genomics. 18 (1) 769. doi:10.1186/s12864-017-4146-z. PMC 5637355. PMID 29020922.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Spaia S, Magoula I, Tsapas G, Vayonas G (2000). "Effect of pyrazinamide and probenecid on peritoneal urate transport kinetics during continuous ambulatory peritoneal dialysis". Peritoneal Dialysis International. 20 (1): 47–52. doi:10.1177/089686080002000109. PMID 10716583. S2CID 19352495.
Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR (September 2000). "Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis". Nature Medicine. 6 (9): 1043–1047. doi:10.1038/79558. PMID 10973326. S2CID 7409751.
Scorpio A, Zhang Y (June 1996). "Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus". Nature Medicine. 2 (6): 662–667. doi:10.1038/nm0696-662. PMID 8640557. S2CID 8579133.

web.archive.org (Global: 1^st place; English: 1^st place)

"Pyrazinamide". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
Donald PR, van Helden PD (2011). Antituberculosis Chemotherapy. Karger Medical and Scientific Publishers. p. 8. ISBN 978-3-8055-9628-2. Archived from the original on 10 September 2017.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Lewis SM, Dirksen SR, Heitkemper MM, Bucher L, Harding M (5 December 2013). Medical-surgical nursing: assessment and management of clinical problems (9th ed.). St. Louis, MO: Mosby. ISBN 978-0-323-10089-2. OCLC 228373703.

Pyrazinamide (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

hdl.handle.net (Global: 66th place; English: 34th place)

ingenta.com (Global: low place; English: low place)

openurl.ingenta.com

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 529^th place; English: 550^th place)

hdl.handle.net (Global: 66^th place; English: 34^th place)

nih.gov (Global: 5^th place; English: 5^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 4^th place; English: 4^th place)